Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
-2.52% $0.963
America/New_York / 17 apr 2024 @ 11:50
FUNDAMENTALS | |
---|---|
MarketCap: | 3.03 mill |
EPS: | -8.88 |
P/E: | -0.110 |
Earnings Date: | Apr 17, 2024 |
SharesOutstanding: | 3.14 mill |
Avg Daily Volume: | 0.0092 mill |
RATING 2024-04-17 |
---|
B |
Neutral |
RATINGS | ||
---|---|---|
Rating CashFlow: | Strong Buy | |
Return On Equity: | Strong Buy | |
Return On Asset: | Strong Sell | |
DE: | Strong Sell | |
P/E: | Neutral | |
Price To Book: | Strong Sell |
QUARTER GROWTHS | ||||||
---|---|---|---|---|---|---|
2/22 | 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | |
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gr.Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Ebit | ||||||
Asset | ||||||
Debt |
PE RATIO: COMPANY / SECTOR |
---|
0.00x |
Company: PE -0.110 | sector: PE -3.05 |
PE RATIO: COMPANY / INDUSTRY |
---|
-0.02x |
Company: PE -0.110 | industry: PE 5.88 |
DISCOUNTED CASH FLOW VALUE |
---|
$2.69 (179.27%) $1.725 |
Date: 2024-04-17 |
Expected Trading Range (DAY) |
---|
$ 0.861 - 1.065 ( +/- 10.60%) |
ATR Model: 14 days |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-24 | Walts Alan Edmund | Buy | 7 500 | Restricted Stock Units |
2024-01-24 | Rubin Steven D | Buy | 7 500 | Restricted Stock Units |
2024-01-24 | Androski Lindsay | Buy | 7 500 | Restricted Stock Units |
2024-01-24 | Aggarwal Sumit | Buy | 60 000 | Restricted Stock Units |
2023-01-30 | Walts Alan Edmund | Buy | 2 859 | Stock Options (Right to Buy) |
INSIDER POWER |
---|
100.00 |
Last 94 transactions |
Buy: 28 846 630 | Sell: 836 099 |
Indicator Signals | |
---|---|
RSI 21 | |
SMA | |
Trend | |
Trend 2 | |
Trend 3 |
Volume Signals | |
---|---|
Price | $0.963 (-2.52% ) |
Volume | 0.0108 mill |
Avg. Vol. | 0.0092 mill |
% of Avg. Vol | 118.00 % |
Signal 1: |
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
Date | Signal | @ | Closed | % |
---|
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.